annb0t
Top 20
Telix Pharmaceuticals Limited(NASDAQ:TLX) on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
IPAX-Linz is a single-arm Phase 2 investigator-initiated trial evaluating the safety, tolerability, and preliminary efficacy of TLX101 therapy in combination with external beam radiation therapy (EBRT).
TLX101 (131I-iodofalan or 131I-IPA) is...
>>> Read more: Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
IPAX-Linz is a single-arm Phase 2 investigator-initiated trial evaluating the safety, tolerability, and preliminary efficacy of TLX101 therapy in combination with external beam radiation therapy (EBRT).
TLX101 (131I-iodofalan or 131I-IPA) is...
>>> Read more: Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
